|
|
| |
| Most Discussed Stocks |
 |
|
|
|
| |
|
News |
| |
|
WILL THE FDA GIVE THE GREEN LIGHT T.... |
10/06/2008 |
|
Has the time come for Provenge, the prostate cancer vaccine developed by Dendreon, to be given marketing approval so it can save condemned metastatic prostate cancer patients’ lives? |
| |
|
PROGENICS: THE HIV DRUG LOOKS PROMI.... |
10/02/2008 |
|
|
| |
|
WE WILL BE ALL RIGHT |
09/25/2008 |
|
We gave you Sequenom and many other winners. Prohost will continue to do the same, hopefully without as much struggling against the greed of those who took advantage of the market deregulation to turn it into a vehicle for self-fulfillment of destructive prophesies at the expense of the serious investors.
We surely believe that America is capable of overcoming this crisis. Yet, our hope is in a reform that stops the greed that tarnished the market’s and America’s strong economy’s reputation.
We will be all right.
|
| |
|
SEQUENOM (SQNM): SUCCESS OF NON INV.... |
09/24/2008 |
|
The results are 100% without manipulation of the fetus and with a simple mother\'s blood test. |
| |
|
CYTRX COMPLETES ITS BUYOUT OF INNOV.... |
09/23/2008 |
|
Cytrx inherited the cancer drug tamibarotene, which has been approved in Japan for acute promyelocytic leukemia (APL). It also inherited three other drug candidates. Read about tamibarotene. Read also about the a stool test that shows successful results in diagnosing colorectal cancer. |
| |
|
|
| |
| |
| |
|
|
Stocks >> Stocks Details |
|
|
| |
|
IMPROVING EXISTING CANCER AND ANTI-VIRAL DRUGS |
|
|
|
ADVENTREX PHARMACEUTICALS
|
| |
|
ADVENTREX PHARMACEUTICALS
(ANS) was known as Biokeys Pharmaceuticals. The firm focuses on improving
existing anti-cancer and antiviral therapies with
technology it licenses from the University of Southern California and the
University of Texas M.D. Anderson Cancer Center. Its lead
drug candidate CoFactor is used
with 5-FU, a commonly used chemotherapy drug, to inhibit a key tumor growth enzyme.
Selone targets
chemotherapy-resistant tumors. Antiviral candidates include HIV vaccines,
compounds that may stop HIV from infecting cells, and a therapy that would
replace an existing antiviral that can only be delivered intravenously. www.adventrx.com
|
| |
| |
| |
| |
| |
| |
|
|
|
|
